CAMTA1-PPP3CA-NFATc4 multi-protein complex mediates the resistance of colorectal cancer to oxaliplatin.


Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
24 Mar 2022
Historique:
received: 04 08 2021
accepted: 24 02 2022
revised: 25 11 2021
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Colorectal cancer is a major contributor to the worldwide prevalence of cancer-related deaths. Metastasis and chemoresistance are the two main causes for colorectal cancer treatment failure, and thus, high mortality. Calmodulin-binding transcription activator 1 (CAMTA1) is involved in tumor growth and development, but its mechanisms of action in the development of colorectal cancer and chemoresistance are poorly understood. Here, we report that Camta1 is a tumor suppressor. Immunohistochemical staining and western blotting analyses of normal and colorectal cancer tissues showed a significantly low expression of Camta1 expression in colorectal cancer tissues, when compared to adjacent normal tissues. In functional in vitro experiments, we observed that Camta1 overexpression significantly decreased the proliferation and invasion capacity of SW620 and SW480 cells, whereas Camta1 knockdown displayed a significant increase in the proliferative and invasive ability of these cells. Subsequently, we examined the effects of Camta1 overexpression and knockdown on the resistance of colorectal cancer cells to oxaliplatin, a common chemotherapeutic drug. Interestingly, the sensitivity of Camta1-overexpressed cells to oxaliplatin was increased, whereas that of Camta1-silenced cells to the same chemotherapeutic drug was decreased. Furthermore, Camta1 knockdown upregulated nuclear factor of activated T cells, cytoplasmic 4 (Nfatc4) mRNA, and protein levels in colorectal cancer cells and downregulated the phosphorylated NFATc4 level. By contrast, Nfatc4 knockdown reversed the resistance of colorectal cancer cells to oxaliplatin caused by Camta1 knockdown. In addition, we show that protein phosphatase 3 catalytic subunit alpha (PPP3CA) is essential for the expression and phosphorylation of NFATc4 caused by Camta1 knockdown, as well as the proliferation, invasion, and chemoresistance of colorectal cancer cells. We show that PPP3CA and CAMTA1 competitively bind to NFATc4, and Camta1 knockdown promotes the dephosphorylation of PPP3CA and suppresses the phosphorylation of NFATc4. To verify the role of CAMTA1 in oxaliplatin resistance in colorectal cancer, we established a xenograft mouse model and show agreement between in vitro and in vivo results.

Identifiants

pubmed: 35332122
doi: 10.1038/s41420-022-00912-x
pii: 10.1038/s41420-022-00912-x
pmc: PMC8948201
doi:

Types de publication

Journal Article

Langues

eng

Pagination

129

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81871984

Informations de copyright

© 2022. The Author(s).

Références

EMBO J. 2011 Aug 19;30(20):4309-22
pubmed: 21857646
Nat Commun. 2019 Feb 8;10(1):663
pubmed: 30737378
Cancer Sci. 2016 Nov;107(11):1543-1549
pubmed: 27554046
Cancer Biother Radiopharm. 2017 Jun;32(5):149-160
pubmed: 28622036
Cell Physiol Biochem. 2019;52(6):1503-1516
pubmed: 31112017
Mol Ther Methods Clin Dev. 2016 Apr 13;3:16017
pubmed: 27110581
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
J Exp Clin Cancer Res. 2020 Nov 5;39(1):232
pubmed: 33153498
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
J Exp Clin Cancer Res. 2019 Sep 6;38(1):393
pubmed: 31492150
Br J Cancer. 1997;75(9):1381-4
pubmed: 9155063
Chromosoma. 2018 Jun;127(2):175-186
pubmed: 29322240
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Curr Cancer Drug Targets. 2007 Jun;7(4):343-53
pubmed: 17979629
Nutrients. 2019 Jan 14;11(1):
pubmed: 30646512
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Gastroenterology. 2006 Dec;131(6):1913-24
pubmed: 17087931
Curr Mol Med. 2013 May;13(4):543-54
pubmed: 22950383
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Am Fam Physician. 1999 Jun;59(11):3083-92
pubmed: 10392591
Mol Oncol. 2019 Feb;13(2):109-131
pubmed: 30520562
Mol Cell Biol. 2002 Jun;22(11):3892-904
pubmed: 11997522
Pancreatology. 2010;10(4):416-22
pubmed: 20720442

Auteurs

Ruijun Pan (R)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, China.

Zhou Zhang (Z)

Department of General Surgery, Shidong Hospital Yangpu District, Shidong Hospital, Yangpu District, Shanghai, China.

Hongtao Jia (H)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, China.

Junjun Ma (J)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, China.

Chao Wu (C)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, China.

Pei Xue (P)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, China.

Wei Cai (W)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, China.

Xiaoping Zhang (X)

Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China. zxpsibs@163.com.
Shanghai Center of Thyroid Diseases, Tongji University School of Medicine, Shanghai, 200072, China. zxpsibs@163.com.

Jing Sun (J)

Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China. jingsun1982@sina.cn.
Shanghai Minimally Invasive Surgery Center, Shanghai, China. jingsun1982@sina.cn.

Classifications MeSH